Podcast: Understanding AATD
Understanding alpha-1 antitrypsin deficiency
Alpha-1 antitrypsin deficiency is a rare genetic disease that predisposes individuals to an increased risk of developing lung and liver complications. Join our experts – Pavel Strnad (Germany), Jeffrey Teckman (USA), and Marc Miravitlles (Spain) – for this accredited podcast series on the importance of early identification, diagnosis, treatment, and management of alpha-1 antitrypsin deficiency.
This accredited podcast series is designed for gastroenterology, hepatology, and respiratory specialists and all healthcare professionals involved in the care of people with alpha-1 antitrypsin deficiency.
After listening to all four episodes, there are a total of 1.5 CME credits available based on successful completion of a quiz and evaluation form. You will automatically be directed between episodes, and then to the quiz.
What is AATD, and how does it impact the liver and the lung?
Episode 1. What are the hepatic and pulmonary consequences of alpha-1 antitrypsin deficiency? Pavel Strnad and Marc Miravitlles examine its incidence, physiological role in homeostasis, associated comorbidities, the impact of COVID-19, and emerging therapeutic approaches.
Meet the experts
Pavel Strnad, MD
Pavel Strnad is a full professor and leading physician at University Hospital Aachen, Germany. He heads his own research lab focusing on translational gastroenterology and the European initiative for the study of alpha-1 antitrypsin deficiency–associated liver disease. His interests include metabolic liver disease, liver cirrhosis and its complications, as well as the analysis of complex datasets. His clinical focus is on emerging drugs, end-stage liver disease, and liver transplantation.
Disclosures: Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, CSL Behring, Dicerna Pharmaceuticals, Grifols, GSK, Intellia Therapeutics, Novo Nordisk, Ono Pharmaceutical, Takeda, and Vertex Pharmaceuticals.
Jeffrey Teckman, MD
Jeffrey Teckman is Professor of Pediatrics and Biochemistry at Saint Louis University School of Medicine and Cardinal Glennon Children's Hospital in Missouri, USA. He was named the Drs. James and Patricia Monteleone Endowed Chair in Pediatric Gastroenterology and Hepatology. He has studied liver injury and the model of alpha-1 antitrypsin deficiency for 30 years, and has participated in clinical research studies across a variety of diseases including alpha-1, cystic fibrosis, hepatitis B, hepatitis C, and metabolic disorders. He holds several patents related to liver disease and is a leader in advancing new therapies for alpha-1 disease to clinical trials.
Disclosures: Advisory board or panel fees from BioMarin and Takeda. Consultancy fees from Arrowhead, Beam Therapeutics, BioMarin, Camp4 Therapeutics, Centessa, Dicerna, Intellia, Korro Bio, NeuBase, Novo Nordisk, Takeda, UniQure, and Vertex. Grants research support from Arrowhead, BioMarin, Camp4 Therapeutics, Korro Bio, Takeda, UniQure, and Vertex.
Marc Miravitlles, MD, PhD
Marc Miravitlles is a senior researcher and consultant at Vall d’Hebron University Hospital in Barcelona, Spain. He served as Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international chronic obstructive pulmonary disease (COPD) guidelines, including the American Thoracic Society (ATS)/ERS guidelines on exacerbations of COPD and the ERS statement on management of respiratory disease in alpha-1 antitrypsin deficiency. He founded the Spanish Registry for alpha-1 antitrypsin deficiency in 1992 and has been the co-chair of the European Alpha-1 Antitrypsin Deficiency Research Collaboration (EARCO) Registry of the ERS since 2018.
Disclosures: Consultancy fees from Atriva Therapeutics, CSL Behring, Grifols, Inhibrx, Mereo Biopharma (relationship terminated), Novo Nordisk, ONO Pharma (relationship terminated), Spin Therapeutics (relationship terminated), and Takeda. Grants/research support from Grifols. Speaker’s bureau fees from CSL Behring, Grifols, Kamada, and Takeda.
Sponsorship statement
Developed independently by EPG Health, which received educational funding from Takeda, awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MEDTHORITY. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation #4008163.
Professions in scope for this activity are listed below.
Physicians
Amedco LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.